Moexipril Hydrochloride
CI-925 · Perdix · SPM-925 · Univasc · RS-10085 · Fempress · RS-10085-197 · Moexipril HCl - Bio-X ?
식별자 및 물리적 특성
| CAS No. | 82586-52-5 |
|---|---|
| 분자식 | C27H35ClN2O7 |
| 평균 분자량 | 535 g/mol |
| 단동위원소 질량 | 534.2132792 g/mol |
| SMILES | CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl |
| InChIKey | JXRAXHBVZQZSIC-JKVLGAQCSA-N |
| PubChem CID | 54889 |
| ChEMBL | CHEMBL1200534 |
| ChEBI | CHEBI:6961 |
| EC No. | 617-363-1 |
| DTXSID | DTXSID7044267 |
화학 및 물리적 성질
| 극성 표면적 | 114 |
|---|---|
| 수소 결합 공여자 수 | 3 |
| 수소 결합 수용자 수 | 8 |
| 회전 가능 결합 수 | 12 |
| 무거운 원자 수 | 37 |
| 형식 전하 | 0 |
| 복잡도 | 742 |
| 녹는점 | 141-1610C |
| 저장 조건 | 2-8°C |
| 용해도 | H2O: 가용성32mg/mL |
| 물리적 상태 | 가루 |
| 색상 | White to off-white |
| 용해도 | H2O: 32mg/mL |
| InChIKey | JXRAXHBVZQZSIC-JKVLGAQCSA-N |
| SMILES | Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3cc(OC)c(OC)cc3C[C@H]2C(O)=O |
화학적 성질
Crystalline Solid
안전 및 규제
| GHS 분류 | WarningH400 (95.1%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]P273, P391, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Hazard Classes and Categories | Aquatic Acute 1 (95.1%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Moexipril hydrochlorideAmbiguous-DILI-concern3Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during LactationBecause no information is available on the use of moexipril during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and Breastmilk |
| 수질 위해 등급(WGK) | 3 |
| RTECS 번호 | NW7174500 |
| 운송 번호(UN) | UN 3077 9/PG 3 |
| 관세 코드 | 2933492250 |
| 위험 문구(R) | 50 |
| 위험 표시 | N |
| 안전 문구(S) | 60 |
| 위험 등급 | Aquatic Acute 1 |
| 저장 분류 | 11 - Combustible Solids |
용도
개요
Moexipril hydrochloride is a novel ACE inhibitor first marketed in the U.S.A. for the treatment of hypertension as a monotherapy and as a second-line therapy in combination with diuretics or calcium antagonists. Like other ACE inhibitors, moexipril is a prodrug that is converted in the liver to its diacid moexiprilat which is the active agent. Moexipril displays a higher in vitro inhibitory potency to ACE than enalapril although its effectiveness in reduction of blood pressure in hypertensive patients is similar to that seen with enalapril. It is orally active with a rapid onset and prolonged duration of action. Excellent tolerability has been reported. Moexipril is distinguished by its lower cost than other marketed ACE inhibitors.
용도
Angiotensin converting enzyme (ACE) inhibitor; dimethoxy analog of quinapril